![David Lubner](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
David Lubner
Director/Board Member at
DYNE THERAPEUTICS, INC.
Net worth: 1 $ as of 31/07/2026
Profile
David Charles Lubner is currently an Independent Director at Crescent Biopharma, Inc. (since 2025), Gemini Therapeutics Sub, Inc. (since 2020), Cerevance, Inc. (since 2020), Dyne Therapeutics, Inc. (since 2020), Ichnos Glenmark Innovation, Inc., and Braveheart Bio, Inc. (since 2026).
He is also a Partner at RA Capital Management LP (Private Equity) and a Venture Partner at RA Ventures, Inc., both since 2025.
Additionally, he is a Member of The American Institute of Certified Public Accountants.
Formerly, he was a Director at NightstaRx Ltd. He served as Independent Non-Executive Director at Nightstar Therapeutics Ltd. from 2017 to 2019, Independent Director at Therapeutics Acquisition Corp.
from 2020 to 2021, Independent Director at Vor Biopharma, Inc. from 2020 to 2025, Independent Director at Cargo Therapeutics, Inc. from 2023 to 2025, Independent Director at Gemini Therapeutics, Inc. from 2020 to 2022, Independent Director at POINT Biopharma Global, Inc. from 2021 to 2023, and Independent Director at Arcellx, Inc. from 2020 to 2026.
Earlier roles include Chief Financial Officer at PharMetrics, Inc. from 1999 to 2005, Chief Financial Officer & Senior Vice President at Tetraphase Pharmaceuticals, Inc. from 2010 to 2016, Chief Financial Officer, Secretary & Executive VP at Ra Pharmaceuticals, Inc. from 2016 to 2020, and Chief Financial Officer & Vice President at ProScript, Inc. from 1996 to 1999.
Education includes a graduate degree from Bentley University conferred in 1993 and an undergraduate degree from Northeastern University conferred in 1987.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
0.07% | 07/08/2026 | 55,555 ( 0.07% ) | 1 $ | 31/07/2026 |
-.--% | 02/06/2026 | 0 ( -.--% ) | - $ | 31/07/2026 |
| 05/06/2026 | 0 ( -.--% ) | - $ | 31/07/2026 |
David Lubner active positions
| Companies | Position | Start |
|---|---|---|
| DYNE THERAPEUTICS, INC. | Director/Board Member | 01/03/2020 |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of healthcare and life sciences. It provides financing for pre-seed, seed stage, early stage and growth capital requirements . The firm acts as a lead and co-investor, makes follow-on investments and has a board seat requirement. | Private Equity Analyst | 01/09/2025 |
Cerevance, Inc.
 Cerevance, Inc. Medical SpecialtiesHealth Technology Develops novel therapeutics for neurological and psychiatric disorders | Director/Board Member | 08/12/2020 |
Ichnos Sciences, Inc.
 Ichnos Sciences, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops biologics in oncology | Director/Board Member | - |
Gemini Therapeutics Sub, Inc.
 Gemini Therapeutics Sub, Inc. BiotechnologyHealth Technology Develops drugs for dry age-related macular degeneration and associated rare genetic diseases | Director/Board Member | 28/04/2020 |
The American Institute of Certified Public Accountants
 The American Institute of Certified Public Accountants Miscellaneous Commercial ServicesCommercial Services Association of accountants | Corporate Officer/Principal | - |
RA Ventures, Inc.
 RA Ventures, Inc. Real Estate DevelopmentFinance RA Ventures, Inc., operating as RA Capital Management, is a multi-stage investment and company-building firm focused on healthcare, life sciences, and climate and sustainability technologies. The private company is based in MN. The firm invests in and supports companies developing drugs, medical devices, diagnostics, research tools, and environmental solutions aimed at improving human and planetary health. RA Capital employs an evidence-based, data-driven investment approach supported by internal research teams, and offers strategic support including incubation, American company creation, financing, technology transfer, and executive recruitment. RA Capital also supports social responsibility initiatives such as affordable drug access and sustainable environmental solutions. The firm collaborates with academia and entrepreneurs to translate scientific discoveries into products, provides flexible models for founder involvement, and fosters community engagement and knowledge sharing through online platforms. | Corporate Officer/Principal | 01/10/2025 |
Former positions of David Lubner
| Companies | Position | End |
|---|---|---|
| ARCELLX, INC. | Director/Board Member | 28/04/2026 |
| VOR BIOPHARMA INC. | Director/Board Member | 26/08/2025 |
| ░░░░ ░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Training of David Lubner
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
62
1st degree connections
21
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 21 |
|---|---|
PharMetrics, Inc.
 PharMetrics, Inc. Miscellaneous Commercial ServicesCommercial Services Provides healthcare market insights based on longitudinal and patient-centric information | Commercial Services |
Tetraphase Pharmaceuticals, Inc.
 Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel antibiotics | Health Technology |
Ra Pharmaceuticals, Inc.
 Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of glomerulonephritis, kidney disease and cardiovascular disease | Health Technology |
The American Institute of Certified Public Accountants
The American Institute of Certified Public Accountants Miscellaneous Commercial ServicesCommercial Services Association of accountants | Commercial Services |
ProScript, Inc.
 ProScript, Inc. Pharmaceuticals: MajorHealth Technology Develops anti-cancer treatments | Health Technology |
Bentley University
 Bentley University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Northeastern University
 Northeastern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
RA Ventures, Inc.
RA Ventures, Inc. Real Estate DevelopmentFinance RA Ventures, Inc., operating as RA Capital Management, is a multi-stage investment and company-building firm focused on healthcare, life sciences, and climate and sustainability technologies. The private company is based in MN. The firm invests in and supports companies developing drugs, medical devices, diagnostics, research tools, and environmental solutions aimed at improving human and planetary health. RA Capital employs an evidence-based, data-driven investment approach supported by internal research teams, and offers strategic support including incubation, American company creation, financing, technology transfer, and executive recruitment. RA Capital also supports social responsibility initiatives such as affordable drug access and sustainable environmental solutions. The firm collaborates with academia and entrepreneurs to translate scientific discoveries into products, provides flexible models for founder involvement, and fosters community engagement and knowledge sharing through online platforms. | Finance |
NightstaRx Ltd.
 NightstaRx Ltd. Medical/Nursing ServicesHealth Services development of therapies for retinal dystrophies | Health Services |
Arcellx, Inc.
 Arcellx, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies | Health Technology |
Gemini Therapeutics Sub, Inc.
Gemini Therapeutics Sub, Inc. BiotechnologyHealth Technology Develops drugs for dry age-related macular degeneration and associated rare genetic diseases | Health Technology |
Cerevance, Inc.
Cerevance, Inc. Medical SpecialtiesHealth Technology Develops novel therapeutics for neurological and psychiatric disorders | Health Technology |
Vor Biopharma, Inc.
 Vor Biopharma, Inc. BiotechnologyHealth Technology Engages in developing cell therapies | Health Technology |
Nightstar Therapeutics Ltd.
 Nightstar Therapeutics Ltd. BiotechnologyHealth Technology Operates as a gene therapy company that develops novel treatments for patients suffering from inherited retinal diseases | Health Technology |
Dyne Therapeutics, Inc.
 Dyne Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics to treat muscle diseases | Health Technology |
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of healthcare and life sciences. It provides financing for pre-seed, seed stage, early stage and growth capital requirements . The firm acts as a lead and co-investor, makes follow-on investments and has a board seat requirement. | Finance |
Ichnos Sciences, Inc.
Ichnos Sciences, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops biologics in oncology | Health Technology |
Therapeutics Acquisition Corp.
 Therapeutics Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
Gemini Therapeutics, Inc.
 Gemini Therapeutics, Inc. BiotechnologyHealth Technology Develops drugs for dry age-related macular degeneration and associated rare genetic diseases | Health Technology |
POINT Biopharma Global, Inc.
 POINT Biopharma Global, Inc. BiotechnologyHealth Technology Develops radioligand therapies for the treatment of cancer | Health Technology |
Cargo Therapeutics, Inc.
 Cargo Therapeutics, Inc. BiotechnologyHealth Technology Engages in generation of adoptive cell therapies for cancer treatment | Health Technology |
- Stock Market
- Insiders
- David Lubner
